Aligned with this perspective, recent studies suggest that enhanced CCNE1 mRNA expression levels in patients with breast cancer are associated with resistance to palbociclib (33, 48), which was recapitulated by our current findings supporting that CCNE1 overexpression is sufficient to induce palbociclib resistance in HNSCC cells. This evidence concerns the gene CCNE1 and breast cancer.